CDTX · Insider Trading
Cidara Therapeutics, Inc.
Every open-market purchase and sale reported by CDTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-07 | James Merson | Director | D | −17,475 deriv. | — |
| 2026-01-07 | Ryan Spencer | Director | D | −17,475 deriv. | — |
| 2026-01-07 | Joshua Resnick | Director | D | −27,279 deriv. | — |
| 2026-01-07 | Shane Ward | COO & CLO | D | −25,083 | −$5.56M |
| 2026-01-07 | Bonnie L Bassler | Director | D | −15 | −$3.32K |
| 2026-01-07 | Frank Karbe | Chief Financial Officer | D | −50,651 | −$1.67M |
| 2026-01-07 | Jeffrey Stein | President & CEO | D | −75,640 | −$16.75M |
| 2026-01-07 | Carin Canale-Theakston | Director | D | −35,375 deriv. | — |
| 2026-01-07 | Chrysa Mineo | Director | D | −3,320 | −$735.38K |
| 2026-01-07 | Theodore R Schroeder | Director | D | −41,100 deriv. | — |
| 2026-01-07 | Jeffrey Stein | President & CEO | MIXED | −1,864 | — |
| 2026-01-07 | Daniel D Burgess | Director | D | −150 | −$33.23K |
| 2026-01-07 | Nicole Negar Davarpanah | Chief Medical Officer | D | −20,886 | −$2.78M |
| 2025-12-29 | Nicole Negar Davarpanah | Chief Medical Officer | G | −450 | — |
| 2025-12-29 | Jeffrey Stein | President & CEO | G | −5,425 | — |
| 2025-12-12 | Frank Karbe | Chief Financial Officer | F | −7,290 | −$1.60M |
| 2025-12-12 | Nicole Negar Davarpanah | Chief Medical Officer | F | −10,332 | −$2.27M |
| 2025-12-12 | Shane Ward | COO & CLO | MIXED | −15,041 | −$5.31M |
| 2025-12-12 | Jeffrey Stein | President & CEO | F | −2,285 | −$501.79K |
| 2025-09-15 | Nicole Negar Davarpanah | Chief Medical Officer | Sell | −474 | −$29.80K |
| 2025-06-30 | Rajeev M. Shah | Director | Buy | +9,090,908 | +$400.00M |
| 2025-06-18 | Bonnie L Bassler | Director | A | +11,100 deriv. | — |
| 2025-06-18 | Chrysa Mineo | Director | A | +11,100 deriv. | — |
| 2025-06-18 | Carin Canale-Theakston | Director | A | +11,100 deriv. | — |
| 2025-06-18 | Joshua Resnick | Director | A | +5,079 deriv. | — |
| 2025-06-18 | Ryan Spencer | Director | A | +11,100 deriv. | — |
| 2025-06-18 | James Merson | Director | A | +11,100 deriv. | — |
| 2025-06-18 | RA CAPITAL MANAGEMENT, L.P. | Director | A | +20,316 deriv. | — |
| 2025-06-18 | Daniel D Burgess | Director | A | +11,100 deriv. | — |
| 2025-06-18 | Theodore R Schroeder | Director | A | +11,100 deriv. | — |
| 2025-06-04 | Chrysa Mineo | Director | Buy | +3,320 | +$73.90K |
| 2025-05-12 | Nicole Negar Davarpanah | Chief Medical Officer | A | +10,000 | — |
| 2025-04-02 | Jeffrey Stein | President & CEO | A | +275,000 deriv. | — |
| 2025-04-02 | Shane Ward | COO & CLO | A | +25,000 | — |
| 2025-03-13 | Shane Ward | COO & CLO | Sell | −1,664 | −$36.54K |
| 2025-03-13 | Leslie Tari | CHIEF SCIENTIFIC OFFICER | Sell | −1,773 | −$38.94K |
| 2025-02-26 | Frank Karbe | Chief Financial Officer | A | +57,500 | — |
| 2025-01-07 | Joshua Resnick | Director | A | +22,200 deriv. | — |
| 2025-01-07 | RA Capital Healthcare Fund LP | Director | A | +88,800 deriv. | — |
| 2024-12-19 | Daniel D Burgess | Director | A | +20,500 deriv. | — |
| 2024-12-19 | Bonnie L Bassler | Director | A | +16,000 deriv. | — |
| 2024-12-19 | Chrysa Mineo | Director | A | +19,000 deriv. | — |
| 2024-12-19 | Carin Canale-Theakston | Director | A | +16,000 deriv. | — |
| 2024-12-19 | Theodore R Schroeder | Director | A | +20,500 deriv. | — |
| 2024-11-29 | RA Capital Healthcare Fund LP | Director | A | +1,558,864 | +$23.25M |
| 2024-10-02 | Jeffrey Stein | President & CEO | A | +560,888 deriv. | — |
| 2024-10-02 | Leslie Tari | CHIEF SCIENTIFIC OFFICER | A | +150,224 deriv. | — |
| 2024-10-02 | Shane Ward | COO & CLO | A | +135,540 deriv. | — |
| 2024-10-02 | Taylor Sandison | Chief Medical Officer | A | +166,836 deriv. | — |
| 2024-10-02 | Preetam Shah | Chief Financial Officer | A | +130,087 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Rajeev M. Shah | Director | 3,365,523 | $745.06M |
| RA Capital Healthcare Fund LP | Director | 1,092,796 | $241.92M |
| Frank Karbe | Chief Financial Officer | 43,125 | $9.55M |
| Leslie Tari | CHIEF SCIENTIFIC OFFICER | 16,288 | $3.61M |
| Jeffrey Stein | President & CEO | 10,072 | $2.23M |
| Nicole Negar Davarpanah | Chief Medical Officer | 8,333 | $1.84M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CDTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.